Oct 21, 2026, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announced an oral presentation and a poster presentation at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress, taking place Oct 27 – 30, 2026, in Hamburg, Germany.
Abstract ID: OR076
Presentation Title: Transformer Base-edited Autologous CD34+ Cells Reactivate Fetal Hemoglobin in β-thalassemia and Sickle Cell Disease
Speaker: Jia Chen, Ph.D., Professor of ShanghaiTech University / Shanghai Clinical Research and Trial Center, Co-founder of Correctseq
Presentation Time: Oct 30, 2026, 12:00 (CET)
Format: Oral presentation
Session Title: SESSION 12b: Genome Editing III
Abstract ID: P0919
Presentation Title: Treatment of Persistent Chylomicronemia by Editing of the APOC3 Gene with Transformer Base Editor
Presentation Time: Oct 28, 2026, 13:30 - 15:30 (CET)
Format: Poster presentation
Session Title: Poster Session 1
For more information about the meeting, visit: https://www.esgctcongress.com/
About CorrectSequence Therapeutics
CorrectSequence TherapeuticsTM (CorrectseqTM)(www.correctsequence.com) is a clinical-stage biotech company employing its proprietary transformer Base Editor (tBE) to pioneer next-generation gene editing therapies.
The leading pipeline candidate, CS-101, is an innovative HBG-targeting base editing therapy for β-thalassemia. It has completed Phase I clinical trial and advanced into the pivotal clinical trial stage. More than 40 transfusion-dependent β-thalassemia patients from around the world — including China, Laos, Malaysia, and Pakistan have been treated, with the first patient remaining transfusion-independence for nearly 3 years. All the patients in Phase I clinical trial have remained transfusion-free for over a year, achieving clinical cure.
CS-206, an ex vivo gene-editing therapy for sickle cell disease, has enabled the first treated patient from Nigeria to remain free of vaso-occlusive crises (VOCs) for more than 19 months as of today, achieving the primary efficacy endpoint.
CS-121, an in vivo tBE-based gene-editing therapy via lipid nanoparticles (LNPs) for hypertriglyceridemia / familial chylomicronemia, has successfully treated multiple adult and pediatric patients. It is currently at IND-enabling stage, targeting US FDA/China NMPA IND filing.
tBE offers significant advantages in controlling off-target effects and enhancing in vivo editing efficiency, making it ideal for both multiplex editing and precise single-target editing. It is compatible with various delivery system, including ex vivo editing in hematopoietic stem cells (HSCs) and T cells, as well as in vivo editing via LNPs.
We are developing multiple pipeline programs targeting genetic diseases, metabolic disorders, cardiovascular diseases, and oncology.
Our focus on biotechnology innovation, research and development underscores our commitment to providing efficient, reliable and safe solution for unmet medical needs.
